GSK and Theravance file for FFVI approval in the USA and Europe; Talks with Human Genome?
05:37 EDT 16 Jul 2012 | thePharmaLetter
UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) announced on Friday that they had submitted regulatory applications in the USA and European Union for the once-daily investigational medicine fluticasone furoate and..
Original Article: GSK and Theravance file for FFVI approval in the USA and Europe; Talks with Human Genome?
More From BioPortfolio on "GSK and Theravance file for FFVI approval in the USA and Europe; Talks with Human Genome?"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
